Regenxbio has announced its experimental gene therapy for Duchenne muscular dystrophy succeeded in a pivotal clinical trial, meeting its primary efficacy endpoint. The company is now preparing a submission to the FDA, aiming to bring the first one-time treatment for the devastating muscle-wasting disease to market.
The Phase III trial enrolled boys aged 4 to 8, demonstrating statistically significant improvement in motor function compared to placebo. Key efficacy data included a 1.7-point advantage on the North Star Ambulatory Assessment scale at 52 weeks, with treated patients showing preserved ambulation. However, the safety profile was marred by two cases of serious side effects, which the company disclosed but did not detail in the initial announcement.
CEO Curran Simpson expressed confidence in the regulatory pathway, stating the FDA's leadership will have a "mandate on rare disease flexibility" under the current administration. Analysts expect the company to request Priority Review, which could shorten the standard 10-month review period. The company plans to submit a Biologics License Application by mid-2026.
Investor reaction was muted, with shares fluctuating in pre-market trading as Wall Street weighed the positive efficacy data against the safety concerns. The Duchenne gene therapy market is estimated at $2–4 billion annually, and Regenxbio would compete with Sarepta's Elevidys, which has limited commercial uptake due to high cost and insurance hurdles.
Patients and clinicians welcomed the progress, though some experts caution that the serious side effects must be fully characterized to ensure benefit outweighs risk in a pediatric population. The FDA will scrutinize both the durability of efficacy and the safety profile during review.